COMP <GO>
PGNY vs ABBV // EV/EBITDA & P/E VALUATION
Progyny Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PGNY 5
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: PGNY
LAST: $28.40 (+1.90%) • MKT CAP: $2.18B
valuation
20.5x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PGNY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PGNY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.60% | 70.20% | -46.60 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 29.00% | -12.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.5x | 33.3x | -12.80 | PGNY | /valuation <GO> |
| Free Cash Flow Yield | 8.80% | 3.47% | +5.33 | PGNY | /fcf-yield <GO> |
| Operating Margin | 6.60% | 24.60% | -18.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 4.50% | 6.90% | -2.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 8.60% | +1.80 | PGNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.84 | 5.33 | +3.51 | PGNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.0 | 65.1 | -3.08 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 113.1x | -78.50 | PGNY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.18B | $513.86B | -$511.68B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PGNY REV | ABBV REV | PGNY GROSS % | ABBV GROSS % | PGNY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.29B | $61.16B | 23.6% | 70.2% | $191.8M | $17.82B |
| FY 2024 | $1.17B | $56.33B | 21.7% | 70.0% | $173.7M | $17.83B |
| FY 2023 | $1.09B | $54.32B | — | — | $188.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PGNY // BETA —
ABBV // BETA 1.15